These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 11372587

  • 1. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ.
    Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM, Verhoeven CH, Shimada T, Back DJ.
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
    Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA, Kato R, Yamazoe Y.
    Biochem Pharmacol; 1999 Jun 01; 57(11):1297-303. PubMed ID: 10230773
    [Abstract] [Full Text] [Related]

  • 10. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
    J Pharm Sci; 1998 Jul 01; 87(7):845-53. PubMed ID: 9649353
    [Abstract] [Full Text] [Related]

  • 11. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
    Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI.
    J Clin Pharmacol; 1998 Feb 01; 38(2):112-21. PubMed ID: 9549641
    [Abstract] [Full Text] [Related]

  • 12. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
    Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.
    Biochem Pharmacol; 1996 Oct 25; 52(8):1305-9. PubMed ID: 8937439
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
    Nelson MH, Birnbaum AK, Remmel RP.
    Epilepsy Res; 2001 Apr 25; 44(1):71-82. PubMed ID: 11255075
    [Abstract] [Full Text] [Related]

  • 14. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
    Usmani KA, Karoly ED, Hodgson E, Rose RL.
    Drug Metab Dispos; 2004 Mar 25; 32(3):333-9. PubMed ID: 14977868
    [Abstract] [Full Text] [Related]

  • 15. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.
    Epilepsia; 1998 Dec 25; 39(12):1317-23. PubMed ID: 9860067
    [Abstract] [Full Text] [Related]

  • 16. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM, Murray M.
    J Pharmacol Exp Ther; 1997 Feb 25; 280(2):966-73. PubMed ID: 9023313
    [Abstract] [Full Text] [Related]

  • 17. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT.
    Br J Clin Pharmacol; 2001 Nov 25; 52(5):547-53. PubMed ID: 11736863
    [Abstract] [Full Text] [Related]

  • 18. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD.
    J Pharmacol Exp Ther; 2000 May 25; 293(2):453-9. PubMed ID: 10773015
    [Abstract] [Full Text] [Related]

  • 19. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T.
    J Pharmacol Exp Ther; 1997 Nov 25; 283(2):434-42. PubMed ID: 9353355
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ, Clarke SE, Chenery RJ.
    Br J Clin Pharmacol; 1999 Sep 25; 48(3):424-32. PubMed ID: 10510156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.